Acadia Pharmaceuticals Inc. (ACAD) FinancialsACADFinancialAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. (ACAD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is NUPLAZID, accounting for 59.5% of total sales, equivalent to $183.13M. Another important revenue stream is DAYBUE. Understanding this composition is critical for investors evaluating how ACAD navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Acadia Pharmaceuticals Inc. maintains a gross margin of 90.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.29%, while the net margin is 10.23%. These profitability ratios, combined with a Return on Equity (ROE) of 35.74%, provide a clear picture of how effectively ACAD converts its operational activities into shareholder value.

In the context of the broader market, ACAD competes directly with industry leaders such as PBLS and DFTX. With a market capitalization of $4.87B, it holds a significant position in the sector. When comparing efficiency, ACAD's gross margin of 90.81% stands against PBLS's 100.00% and DFTX's N/A. Such benchmarking helps identify whether Acadia Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

The company has shown consistent revenue growth, with Q2 2026 revenue at $307.96 million, a significant increase from previous quarters. The gross margin remains robust at 90.81%, indicating strong profitability.